ArticleThe Lancet. Oncology2025
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus.
Article in The Lancet. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis.The Lancet. Oncology · 2026Article
- Promoting expertise knowledge sharing in paediatric virology: An update (Review).Experimental and therapeutic medicine · 2026Review
- Burden and Correlates of Multiple Chronic Infections and Their Associations With Cancer Incidence in Chinese Adults: A Large Case-Cohort Study.International journal of cancer · 2026Article
- Review
- Article
- Review
- Hepatitis D Virus: Enigmas and Gaps of Knowledge.Viruses · 2026Review
- Review
- The Mutational Epidemiology of Childhood Cancer.Clinical chemistry · 2025Review
- Targeting Human Cytomegalovirus as a Novel Approach for Glioblastoma Treatment.Pathogens (Basel, Switzerland) · 2025Review
- Key domains involved in the interaction and assembly of the HCMV terminase complex.Scientific reports · 2025Article
- The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Review
- Does human cytomegalovirus provide a novel therapeutic target for patients with glioblastoma?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.